Scholarlink

<p>L-carnitine, a crucial component in the metabolism of fatty acids, has shown promise as a treatment for malnutrition and cardiovascular disease in hemodialysis patients. The 2025 meta-analysis by Nabi et al., which documented a statistically significant improvement in left-ventricular ejection fraction (LVEF) after L-carnitine supplementation, is the focus of this letter's evaluation of previous data. Although there has been a noticeable increase in systolic performance, there are still conflicting data on diastolic function and left-ventricular mass index (LVMI). Furthermore, it is becoming more widely acknowledged that L-carnitine deficit contributes to malnutrition in patients on maintenance hemodialysis. This highlights the need for thorough, high-quality clinical trials to confirm the therapeutic efficacy of L-carnitine and evaluate its influence on long-term clinical outcomes. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

“Exploring benefits of L-carnitine in hemodialysis: promising findings await clinical application”

  • 期刊论文

  • 发表日期：

    2025年4月25日

查看全文
  • Duaa Abdul Karim

摘要

L-carnitine, a crucial component in the metabolism of fatty acids, has shown promise as a treatment for malnutrition and cardiovascular disease in hemodialysis patients. The 2025 meta-analysis by Nabi et al., which documented a statistically significant improvement in left-ventricular ejection fraction (LVEF) after L-carnitine supplementation, is the focus of this letter's evaluation of previous data. Although there has been a noticeable increase in systolic performance, there are still conflicting data on diastolic function and left-ventricular mass index (LVMI). Furthermore, it is becoming more widely acknowledged that L-carnitine deficit contributes to malnutrition in patients on maintenance hemodialysis. This highlights the need for thorough, high-quality clinical trials to confirm the therapeutic efficacy of L-carnitine and evaluate its influence on long-term clinical outcomes.